A Phase II Study of Atezolizumab Immunotherapy plus Bevacizumab in Patients with Recurrent, Persistent, or Metastatic Cervical Cancer

Full Title

NCI #10010: A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination with Bevacizumab in Patients with Recurrent, Persistent or Metastatic Cervical Cancer (CIRB)


Bevacizumab is an anticancer drug approved to treat advanced cervical cancer and other cancers. It works by inhibiting the development of blood vessels that tumors need to grow and spread. In this study, researchers are assessing the safety and effectiveness of combining bevacizumab with the immunotherapy drug atezolizumab in women with cervical cancer that has metastasized (spread), come back, or continued to grow despite previous treatment.

Atezolizumab is designed to improve the immune system’s ability to recognize and destroy cancer cells by blocking PD-L1, a protein made by some cancers. It is approved for treating bladder and lung cancers; its use in this study is considered investigational. Both atezolizumab and bevacizumab are given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have cervical cancer that has metastasized, come back, or continued to grow despite previous treatment that included bevacizumab.
  • At least 4 weeks must pass between the completion of previous treatment and entry into the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Claire F. Friedman at 646-888-4247.